S0947000
Somatropin
European Pharmacopoeia (EP) Reference Standard
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Prodotti consigliati
Grado
pharmaceutical primary standard
Famiglia di API
somatropin
Produttore/marchio commerciale
EDQM
applicazioni
pharmaceutical (small molecule)
Formato
neat
Temperatura di conservazione
−20°C
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Descrizione generale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Applicazioni
Somatropin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Confezionamento
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Altre note
Sales restrictions may apply.
Prodotti correlati
N° Catalogo
Descrizione
Determinazione del prezzo
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Choose from one of the most recent versions:
Certificati d'analisi (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Servizio Clienti
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Marianne Klose et al.
The Journal of clinical endocrinology and metabolism, 99(1), 101-110 (2013-11-19)
Recent international guidelines suggest pituitary screening in patients with moderate and severe traumatic brain injury (TBI). Predominantly isolated GH deficiency (GHD) was reported in the literature, raising the question of potential methodological bias. Our objective was to assess the prevalence
Editor's commentary: sex hormone priming.
Zvi Laron
Pediatric endocrinology reviews : PER, 11(3), 288-288 (2014-04-11)
Z Gucev et al.
Pediatric endocrinology reviews : PER, 11(3), 337-338 (2014-04-11)
The Second meeting on Rare Diseases in South Eastern Europe (SEE) was held in Skope, Macedonia on November 15-16, 2013. Objective and main data: Rare diseases (RD) are a major problem in developed and especially in countries without affluence. 6-8%
Long-acting growth hormone.
Charlotte Höybye et al.
Paediatric drugs, 15(6), 427-429 (2013-11-20)
Vita Birzniece et al.
European journal of endocrinology, 170(3), 375-383 (2013-12-19)
GH action is attenuated by estrogens and selective estrogen receptor modulators (SERMs) administered orally. During GH therapy in hypopituitary women, co-treatment with raloxifene, a SERM, induced a smaller gain in lean body mass (LBM) compared with estrogen, despite an equal
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.